SI

Sirius Neosight

Lyon, FR · 1 known investors

sirius-neosight.com ↗

Sirius NeoSight develops a patented technology that measures cell membrane fluidity using a fluorescent molecule to detect, isolate and characterise Circulating Tumour Cells (CTCs) from blood samples. Aimed at oncologists, the technology supports early cancer detection, monitoring of recurrence and treatment resistance, and personalised therapy selection for metastatic and aggressive cancers.

Investors · 1

OC

OctalfaLyon · $100K – $2.7M